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379/99, and B/Harbin/7/94. A diagno-
sis of influenza was made based on
seroconversion with at least a fourfold
rise in antibody titer. Based on sero-
conversion, the influenza attack rate
among all pilgrims was 38% (44/115).
The attack rate was 30% among the
vaccinated and 41% among the non-
vaccinated participants (Table) (odds
ratio for influenza in vaccinees =
0.61, p = 0.28). Of the 44 patients, 42
(37%) were infected with influenza A
H3N2; 1 had influenza AH1N1, and 1
had influenza B infection. Six influen-
za A H3N2 patients were dually
infected; two patients seroconverted
to AH1N1, and four patients serocon-
verted to influenza B. Nearly half
(21/44) of the patients with influenza
received a course of antimicrobial
drugs while on the hajj compared with
38% (27/71) of those who did not
seroconvert. The attack rate in the
vaccinated patients was lower than
the rate in nonvaccinated patients,
which is consistent with some protec-
tive effect of the influenza vaccine. 
Even though blood was collected
from five convalescing patients with-
in 3 weeks of their return from the
hajj, some of the patients may have
acquired influenza B infection imme-
diately after their return to the United
Kingdom, as it was the main strain
circulating in the United Kingdom in
late February to March 2003. Many
pilgrims from throughout the world,
some of whom may carry H3N2 drift
variants, mingle closely during the
hajj. This type of exposure increases
the risk for worldwide spread of new
drift variants and other contagious
respiratory diseases (3). Given the
potential for the high influenza attack
rate documented in this study, all pil-
grims, regardless of age, should be
offered influenza vaccination before
they travel on the hajj during winter
months. On-site testing for influenza
should be available to medical servic-
es in Makkah (and countries of ori-
gin), and treatment with a neu-
raminidase inhibitor should be offered
to persons who test positive and have
been symptomatic for <48 hours (4).
This treatment should lessen the
transmission risk to pilgrims during
the crowded events during travel and
on their return home (5). When pil-
grims return from the hajj, physicians
should be informed that pilgrims may
bring back new drift variants of
influenza; physicians should consider
the diagnosis and treat persons at risk
and their close contacts (4).
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To the Editor: Invasive infections
with  Streptomyces  spp. are rare; in
reference to two cases reported in
Emerging Infectious Diseases (1,2),
we describe here the first documented
case of bacteremia with Streptomyces
thermovulgaris. An 81-year-old
woman was admitted to the emer-
gency room of Diakonessenhuis,
Utrecht, the Netherlands, with severe
abdominal pain in the right lower
quadrant and feculent vomitus. The
patient had a history of Crohn’s dis-
ease, for which she had undergone
resection of the ileum and cecum, and
was receiving high-dose corticos-
teroid therapy (prednisone 25 mgLETTERS
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daily). The patient also had steroid-
induced osteoporosis and an internal
pacemaker. On admission, the patient
had a temperature of 35.6°C, a leuko-
cyte count of 8.4 x 109/L with 30%
bandforms, and a C-reactive protein
level of 18 mg/L. Moreover, the
patient had severe metabolic acidosis
and was hemodynamically unstable,
suggesting septic shock subsequent to
a presumed bowel perforation.
Blood samples were drawn and
cultured, and empiric treatment was
initiated with ceftriaxone and metron-
idazole. Exploratory laparotomy
showed colonic inflammation. The
patient was transferred to the inten-
sive care unit postoperatively. On day
9 of hospitalization, the blood culture
taken on day 1 before antimicrobial
drug was started, turned positive in
the automatic blood culture system.
Gram staining showed gram-positive
nocardioform rods, and subculture on
tryptic soy agar with 7% sheep blood
yielded polymorphous colonies that
sunk into the agar and showed fila-
mentous growth.
Despite intensive antimicrobial
and supportive therapy, sepsis pro-
gressed into multiple organ failure
with severe neuropathy. On day 25 of
hospitalization, the patient died.
Autopsy demonstrated no possible
infective focus except severe inflam-
mation of the colon and distal ileum.
Permission for cerebral section was
not granted. The blood isolate showed
strictly aerobic growth at 37°C and
50°C with β-hemolysis and was posi-
tive for catalase, caseinase, gelatinase,
and nitrate reduction; the isolate was
negative for oxidase, urease, and
esculin hydrolysis and was nonmotile
at 37°C. The isolate was sent to the
National Institute of Public Health,
Bilthoven, the Netherlands, for identi-
fication. Biochemical analysis, fatty
acid analysis, and 16S rRNA typing
identified the strain as S. thermovul-
garis. The strain was susceptible to
ceftriaxone (MIC 0.32 µg/mL) by
Etest (BA Biodisk, Solna, Sweden).
Further susceptibility testing per-
formed by agar diffusion showed that
the organism was also susceptible to
amoxicillin, vancomycin, a combina-
tion of trimethoprim and sulfame-
thoxazole, and erythromycin. 
Bacteremia produced by a strain of
S. thermovulgaris, as we report here,
is the first documented case of isola-
tion of this microorganism from
human material. The streptomycetes
are classified as a separate genus
within the aerobic actinomycetes and
are most well known for the many
antimicrobial substances isolated
from the approximately 600 different
species (3). Streptomycetes, aerobic,
spore-forming, gram-positive bacteria
with filamentous growth, are ubiqui-
tous in soil and can cause mycetomas
(4). Streptomycetes are widely dis-
tributed in terrestrial and aquatic habi-
tats with soil, fodder, and compost as
their primary reservoirs. The amount
of actinomycetes (the taxonomic
group to which the streptomycetes
belong) in soil is estimated to be
107–108 microorganisms per gram (5),
and in total biomass equal to that of
all other bacteria together and slightly
less than that of fungi. S. thermovul-
garis belongs to the thermophilic
streptomycetes, which do not grow at
temperatures <37°C and are believed
to affect biodegradation of organic
waste products at higher temperatures
(6). The S. thermovulgaris strains in
the American Type Culture Collection
have been isolated from manure,
manured soil, and compost.
S. anulatus, S. somaliensis, and S.
paraguayensis are the species that
have been implicated most frequently
as causing human disease, but strepto-
mycetes such as S. albus (7), S. coeli-
color,  S. lavendulae,  S. rimosus,  S.
bikiniensis, and S. violaceoruber have
also been implicated (2). Invasive
infections caused by streptomycetes
are very rare, and few cases of bac-
teremia have been reported (1,2,8). 
Reported clinical isolates are often
associated with decreased immunity,
as in the case of S. bikiniensis from a
patient with osteosarcoma (2), and in
the case of Streptomyces  spp. from
patients with HIV (9). Our patient  had
severe immunosuppression as a result
of intensive steroid treatment for ther-
apy-resistant Crohn’s disease. Autopsy
identified no possible focus of infec-
tion other than the patient’s intestines,
which were severely inflamed with
massive ulceration. Cultures taken at
autopsy were negative. 
Because of the large numbers of
streptomycetes in the agricultural
environment, eating contaminated
food probably occurs frequently;
however, in healthy people it will not
lead to invasive infection. In our
patient, the heavily inflamed, ulcerat-
ed gut likely enhanced the opportuni-
ty for infection from the intestines. 
Because it is a soil bacterium,
Streptomyces  spp. would not likely
contaminate a hospital environment.
Moreover, studies have never shown
Streptomyces  spp. as contaminants
(10); therefore, any clinical isolate
should be considered potentially rele-
vant. After antibiotic therapy was ini-
tiated, repeated blood cultures showed
no persisting Streptomyces bac-
teremia, which can be explained by
the strain’s susceptibility to the
antimicrobial agents that were given.
In conclusion, we have described
the first documented case of S. ther-
movulgaris bacteremia. Immuno-
compromised patients are susceptible
to colonization and infection with a
broad range of both common and
uncommon pathogens. Although the
clinical value of positive blood cul-
tures with less common pathogens
such as streptomycetes must always
be carefully weighed, they may not
simply be discarded as contaminants.
The work described in this article
was conducted at the Diakonessenhuis
Utrecht, Utrecht, the Netherlands. LETTERS
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To the Editor: West Nile virus
(WNV) is a mosquito-transmitted fla-
vivirus, widely distributed in Africa,
the Middle East, Asia, and southern
Europe. Since the 1990s, its geo-
graphic distribution has expanded and
caused epidemics of meningoen-
cephalitis (1). Recently introduced
into the United States, it expanded
rapidly from New York throughout
the country and caused illness in
9,862 human patients in 2003 (2). In
France, the first reported WNV out-
break that affected horses and humans
occurred during the summer of 1962
in the Camargue region (1). After
1965, no human or equine WNV
infections were reported until
September 2000, when a large out-
break of equine encephalitis occurred
in France (3). No human cases were
reported at that time. In September
2003, a human living in Fréjus
(Département du Var, southeastern
France) was diagnosed with acute
WNV infection in Nice University
Hospital. At the same time, an equine
case was diagnosed 20 km from the
patient’s home; consequently, public
health authorities initiated a retro-
spective study of patients hospitalized
in the French Mediterranean region in
which viral meningoencephalitis was
suspected. We report four human
cases from Fréjus Hospital.
Twenty patients who had been hos-
pitalized at some time from August 1
to October 15, 2003, for febrile
meningitis, encephalitis, or poly-
radiculoneuritis were screened. Four
patients in whom cerebrospinal fluid
(CSF) analysis indicated a viral cause
were included. In addition, serum
samples from two patients who had
experienced flulike symptoms with
exanthema during the same period
were tested further. Serologic diagno-
sis of acute WNV infection was based
on immunoglobulin (Ig) M-capture
and direct IgG enzyme-linked
immunosorbent assay followed by
80% plaque reduction neutralization
titer (PRNT80) by using the France
2000 WNV strain (3).
Patient 1, 46 years old, and patient
2, 25 years old, had a flulike syn-
drome with maculopapular exanthe-
ma; WNV seroconversion was seen
on a pair of sera collected on days 3
and 16 for patient 1, and days 3 and 12
for patient 2, after onset of fever.
Patients 3 and 4 had meningoen-
cephalitis with maculopapular exan-
thema. In patient 3, a fourfold
increase in WNV neutralizing anti-
bodies was seen in serum samples on
2 consecutive days (days 3 and 15
after onset of fever). In patient 4,
WNV IgM antibodies were detected
in CSF (day 4 after onset of fever),
and neutralizing antibodies (titer =
160) were reported in a serum speci-
men on day 75. Attempts to detect
WNV RNA by reverse transcrip-
tion–polymerase chain reaction, or to
isolate the virus from serum speci-
mens in patients 1 and 2 and CSF in
patient 4, were negative because of
the low level and short duration of
WNV viremia (4). All patients recov-
ered.
On the basis of serologic results,
we describe the first human clinical
WNV infections in France since 1964
(5). The four patients lived in the
same city, had not traveled, and had
an onset of their illness during the last
week of August 2003. Of note, four
clinical infections were identified, but
many more WNV subclinical and
asymptomatic infections likely
occurred simultaneously.
After the reemergence of WNV in
horses in the Camargue region in
2000, surveillance on sentinel birds
(ducks and chickens) showed a low
circulation of WNV in 2001 and 2002
in this area. Meanwhile, no clinical
human or equine cases were detected.
During the summer of 2003, WNV
reemerged in humans 200 km east of
Camargue, in the Département du Var,
along the Mediterranean coast. A